Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
acalabrutinib, accretion, advisor, biopharma, bribery, broadly, burden, capability, colorectal, consummated, consummation, contexture, contrast, council, COVID, cyclophosphamide, deep, Delta, denominated, doxorubicin, ecosystem, ESCALADE, Euro, flagship, fourth, France, French, HalioDx, harmonizing, immune, Immunogram, Immunoscore, incompatibility, knowable, logo, Marseille, migrate, motivate, movement, multimodal, nonmetastatic, occupied, par, pendency, prednisone, predominately, printing, proportion, quickly, Rebecca, resale, revisit, rituximab, SAS, satisfaction, social, SPA, staffing, top, transcriptome, variety, vincristine
Removed:
JJSI, Margin, monitored, noninvasively, virtual
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Anderson Exec Chair Agreement
- 10.2 EX-10.2 Stapley CEO Employement Agreement
- 10.3 EX-10.3 Stapley CEO Cic Agreement
- 10.4 EX-10.4 Haliodx Mou and Spa
- 10.5 EX-10.5 Haliodx Spa
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Related press release
Associated VCYT transcripts
VCYT similar filings
Filing view
External links